glucose, (beta-d)-isomer has been researched along with Left Ventricular Dysfunction in 50 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (28.00) | 24.3611 |
| 2020's | 36 (72.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, Y; Hsiao, YT; Ikegami, R; Katsuumi, G; Minamino, T; Nakao, M; Okuda, S; Shimizu, I; Soga, T; Suda, M; Yoshida, Y | 1 |
| Aboalhasan, E; Arbel, R; Azuri, J; Hammerman, A | 1 |
| Borlaug, BA; Burkhoff, D; Frederiksen, PH; Gustafsson, F; Jensen, J; Kistorp, C; Køber, L; Møller, JE; Omar, M; Poulsen, MK; Schou, M; Videbæk, L | 1 |
| Anand, IS; Berg, DD; Chopra, V; de Boer, RA; Docherty, KF; Hammarstedt, A; Jarolim, P; Jhund, PS; Kosiborod, MN; Langkilde, AM; Lindholm, D; McMurray, JJV; Morrow, DA; Nicolau, JC; O'Meara, E; Sabatine, MS; Sattar, N; Schou, M; Sjöstrand, M; Welsh, P | 1 |
| Packer, M; Zannad, F | 1 |
| de Boer, RA; Docherty, KF; Hammarstedt, A; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McDowell, K; McMurray, JJV; Morrow, DA; O'Meara, E; Ponikowski, P; Sabatine, MS; Sattar, N; Sjöstrand, M; Solomon, SD; Welsh, P | 1 |
| Adamson, C; Bengtsson, O; Damman, K; de Boer, RA; Docherty, KF; Heerspink, HJL; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Vaduganathan, M; Verma, S | 1 |
| Belohlávek, J; Bengtsson, O; Butt, JH; Chiang, CE; Dewan, P; Docherty, KF; Drożdż, J; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Merkely, B; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S | 1 |
| Bengtsson, O; Boulton, DW; Docherty, KF; Greasley, PJ; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Petrie, MC; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Yeoh, SE | 1 |
| Ali, M; Andersen, CF; Ersbøll, MK; Faber, J; Forman, JL; Frederiksen, PH; Gustafsson, F; Jensen, J; Kistorp, C; Køber, L; Larsen, JH; Møller, JE; Omar, M; Schou, M; Tuxen, C | 1 |
| Anker, SD; Bhatt, DL; Butler, J; Harrington, J; Hernandez, AF; Jones, WS; Petrie, MC; Sumin, M; Udell, JA; Vedin, O; Zwiener, I | 1 |
| Fu, Z; Husain, M; Ilkayeva, O; Inzucchi, SE; Javaheri, A; Jones, P; Kosiborod, MN; Kwee, LC; Lanfear, DE; Margulies, KB; McGuire, DK; Mentz, RJ; Nassif, ME; Newgard, CB; Pitt, B; Scirica, BM; Selvaraj, S; Shah, SH; Windsor, SL | 1 |
| Bengtsson, O; Biering-Sørensen, T; Butt, JH; DeFilippis, EM; Dewan, P; Docherty, KF; Fiuzat, M; Jhund, PS; Johansen, ND; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Sabatine, MS; Sjöstrand, M; Solomon, SD; Vaduganathan, M | 1 |
| Ferry, A | 1 |
| Hao, Z; Zhang, Y | 1 |
| Anand, I; Berg, DD; de Boer, RA; Docherty, KF; Hammarstedt, A; Jarolim, P; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McDowell, K; McMurray, JJV; Morrow, DA; O'Meara, E; Osmanska, J; Ponikowski, P; Sabatine, MS; Sattar, N; Schou, M; Sjöstrand, M; Solomon, SD; Welsh, P | 1 |
| Austin, B; Drazner, MH; Fong, MW; Givertz, MM; Gordon, RA; Husain, M; Inzucchi, SE; Jermyn, R; Katz, SD; Khariton, Y; Kosiborod, M; Lamba, S; Lanfear, DE; LaRue, SJ; Lindenfeld, J; Malone, M; Margulies, K; McGuire, DK; Mentz, RJ; Mutharasan, RK; Nassif, ME; Pitt, B; Pursley, M; Scirica, BM; Tang, F; Umpierrez, G; Windsor, SL | 1 |
| Anand, IS; Bělohlávek, J; Bengtsson, O; Böhm, M; Chiang, CE; Chopra, VK; de Boer, RA; DeMets, DL; Desai, AS; Diez, M; Docherty, KF; Drozdz, J; Dukát, A; Ge, J; Held, C; Howlett, JG; Inzucchi, SE; Jhund, PS; Katova, T; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Ljungman, CEA; Martinez, FA; McMurray, JJV; Merkely, B; Nicolau, JC; O'Meara, E; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S; Verma, S; Vinh, PN | 1 |
| Cauchon, M; Dussault, C; Huard, G; Lanthier, L; Plourde, MÉ | 1 |
| Sullivan, K; Van Spall, HGC | 1 |
| Borghi, C; Cicero, AFG | 1 |
| Dau, NQ; Peled, H | 1 |
| Mehra, MR; Vieira, JL | 1 |
| Docherty, KF; Jhund, PS; McMurray, JJV | 1 |
| de Boer, RA; de Menezes Montenegro, L; Heerspink, HJL; Hillebrands, JL; Oberdorf-Maass, SU; Silljé, HHW; van Goor, H; Westenbrink, BD; Yurista, SR | 1 |
| Anand, I; Belohlávek, J; Bengtsson, O; Böhm, M; Boulton, D; Chiang, CE; Chopra, VK; de Boer, RA; Desai, AS; Diez, M; Docherty, KF; Drozdz, J; Dukát, A; Ge, J; Greasley, PJ; Howlett, J; Inzucchi, SE; Jhund, PS; Johanson, P; Katova, T; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Ljungman, CEA; Martinez, FA; McMurray, JJV; Merkely, B; Nicolau, JC; O'Meara, E; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S; Verma, S; Vinh, PN | 1 |
| Choy, AMJ; Donnan, PT; Fathi, A; Gandy, S; George, J; Houston, JG; Khan, F; Lang, CC; Mohan, M; Mordi, IR; Pearson, ER; Singh, JSS; Struthers, AD; Vickneson, K | 1 |
| Ivkin, D; Karpov, A; Kaschina, E; Krasnova, M; Kulikov, A; Okovityi, S; Smirnov, A | 1 |
| Amorosi, A; De Rosa, S; Iaconetti, C; Indolfi, C; Mignogna, C; Polimeni, A; Sabatino, J; Sorrentino, S; Spaccarotella, C; Tammè, L; Yasuda, M | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Jaiwongkam, T; Kerdphoo, S; Lahnwong, S; Palee, S; Sriwichaiin, S | 1 |
| Asensio Lopez, MDC; Bayes-Genis, A; Fernandez Del Palacio, MJ; Hernandez Vicente, A; Hernandez-Martinez, A; Lax, A; Pascual Figal, DA; Saura Guillen, E | 1 |
| Bruun, NE; Brønd, JC; Faber, J; Forman, JL; Fosbøl, EL; Gustafsson, F; Gustafsson, I; Jensen, J; Kistorp, C; Køber, L; Møller, JE; Omar, M; Poulsen, MK; Schou, M; Tuxen, C; Videbæk, L | 1 |
| Badimon, JJ; Flores-Umanzor, EJ; Fuster, V; Garcia-Ropero, A; Ishikawa, K; Picatoste, B; Requena-Ibanez, JA; San Antonio, R; Santos-Gallego, CG; Sanz, J; Vargas-Delgado, AP; Watanabe, S | 1 |
| Bengtsson, O; Berg, DD; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Murphy, SA; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Verma, S | 1 |
| Abe, M; Hoshino, K; Kai, T; Nakamura, J; Oka, S; Watanabe, A; Watanabe, K | 1 |
| Fu, S; Li, Y; Qian, Z; Wu, Y; Yang, D; Zhu, L | 1 |
| Chai, D; Chen, X; Chu, Y; Du, H; Lin, J; Lin, X; Liu, J; Ma, K; Ruan, Q; Xie, H; Xu, C; Zeng, J; Zhang, H; Zhang, Y | 1 |
| Doi, T; Hirata, KI; Matsumoto, K; Mochizuki, Y; Sano, H; Shite, J; Soga, F; Takaoka, H; Tanaka, H; Tatsumi, K; Toki, H | 1 |
| Cheng, KK; Ghosh, S; Gokhale, K; Hanif, W; Kumarendran, B; Marshall, T; Narendran, P; Nirantharakumar, K; Thomas, GN; Toulis, KA; Willis, BH | 1 |
| Farhat, A; Hajjar, R; Hammoudi, N; Jeong, D; Komajda, M; Lebeche, D; Mayoux, E; Singh, R | 1 |
| Gupte, M; Lal, H; Umbarkar, P | 1 |
| Calogero, E; Di Bello, V; Fabiani, I; Natali, A; Nesti, L | 1 |
| Chattipakorn, N; Chattipakorn, SC; Sa-Nguanmoo, P; Siri-Angkul, N; Sivasinprasasn, S; Tanajak, P; Thummasorn, S | 1 |
| Abassi, Z; Hollander, K; Landa, N; Leor, J; Naftali-Shani, N; Rath, L; Rosenthal, T; Younis, F | 1 |
| Connelly, KA; Desjardins, JF; Gilbert, RE; Thai, K; Zhang, Y | 1 |
| de Boer, RA; Hillebrands, JL; Oberdorf-Maass, SU; Pavez Giani, MG; Schouten, EM; Silljé, HHW; van Goor, H; van Veldhuisen, DJ; Westenbrink, BD; Yurista, SR | 1 |
| Polovina, MM; Seferović, JP; Seferović, PM | 1 |
| Ayer, A; Cariou, B; Charpentier, F; Dollet, L; Jagu, B; Joubert, M; Le May, C; Magré, J; Manrique, A; Marechal, X; Montaigne, D; Prieur, X; Staels, B; Tesse, A; Toumaniantz, G | 1 |
| Cao, W; Liu, J; Lu, D; Peng, X; Qi, R; Wang, H; Wang, Y; Zhang, W | 1 |
| Deng, LC; Gao, CH; Shen, D; Shen, WS; Zhang, H | 1 |
16 trial(s) available for glucose, (beta-d)-isomer and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical Trial.
Topics: Benzhydryl Compounds; Blood Volume; Chronic Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart Failure; Humans; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left | 2022 |
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF.
Topics: Aged; Benzhydryl Compounds; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Uric Acid; Ventricular Dysfunction, Left | 2022 |
Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Ventricular Dysfunction, Left | 2022 |
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Frailty; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2022 |
The effect of empagliflozin on contractile reserve in heart failure: Prespecified sub-study of a randomized, double-blind, and placebo-controlled trial.
Topics: Aged; Benzhydryl Compounds; Double-Blind Method; Female; Glucose; Glucosides; Heart Failure; Humans; Male; Middle Aged; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Symporters; Ventricular Dysfunction, Left | 2022 |
Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart Failure; Humans; Myocardial Infarction; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left | 2022 |
Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left | 2022 |
Different Doses of Empagliflozin in Patients with Heart Failure with Reduced Ejection Fraction.
Topics: Acute Kidney Injury; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Hypotension; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2022 |
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2019 |
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left | 2019 |
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left | 2020 |
Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial.
Topics: Aged; Benzhydryl Compounds; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucosides; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Placebos; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Remodeling | 2020 |
Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial.
Topics: Accelerometry; Activities of Daily Living; Benzhydryl Compounds; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Outcome Assessment, Health Care; Peptide Fragments; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left | 2020 |
Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Disease Progression; Double-Blind Method; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Numbers Needed To Treat; Proportional Hazards Models; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Ventricular Dysfunction, Left | 2021 |
Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial.
Topics: Adult; Aged; Benzhydryl Compounds; Cardiomyopathies; Diabetes Mellitus, Type 2; Disease Progression; Female; Glucosides; Humans; Hypoglycemic Agents; Italy; Male; Middle Aged; Research Design; Ventricular Dysfunction, Left | 2017 |
Protective effects of salidroside on epirubicin-induced early left ventricular regional systolic dysfunction in patients with breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antioxidants; Breast Neoplasms; Dose-Response Relationship, Drug; Double-Blind Method; Echocardiography; Epirubicin; Female; Glucosides; Humans; Middle Aged; Phenols; Reactive Oxygen Species; Rhodiola; Ventricular Dysfunction, Left | 2012 |
34 other study(ies) available for glucose, (beta-d)-isomer and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Empagliflozin maintains capillarization and improves cardiac function in a murine model of left ventricular pressure overload.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Blood Pressure; Cardiotonic Agents; Disease Management; Disease Models, Animal; Gene Expression Profiling; Glucosides; Heart Failure; Immunohistochemistry; Metabolome; Metabolomics; Mice; Microcirculation; Models, Biological; Norepinephrine; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Dysfunction, Left | 2021 |
Dapagliflozin Versus Sacubitril-Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2022 |
Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Clinical Trials as Topic; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Numbers Needed To Treat; Proportional Hazards Models; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2022 |
Do the Favorable Effects of Digoxin and SGLT2 Inhibitors Really Differ in Patients with Heart Failure and a Reduced Ejection Fraction? A Provocative Side-by-Side Examination of Trial Outcomes.
Topics: Diabetes Mellitus, Type 2; Digoxin; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left | 2022 |
Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Hyponatremia; Sodium; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2022 |
Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Cardiomyopathies; Fatty Acids; Female; Glucosides; Heart Failure; Humans; Ketones; Ketosis; Male; Middle Aged; Quality of Life; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left | 2022 |
Dapagliflozin for patients with heart failure and reduced ejection fraction.
Topics: Adult; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left | 2022 |
Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left | 2023 |
Topics: Adult; Benzhydryl Compounds; Clinical Trials as Topic; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug-Related Side Effects and Adverse Reactions; Female; Glucosides; Heart Failure; Humans; Male; Mortality; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left | 2020 |
Dapagliflozin reduced worsening HF or CV death in HF with reduced ejection fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left | 2020 |
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left | 2020 |
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left | 2020 |
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left | 2020 |
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. Reply.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left | 2020 |
Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Disease Models, Animal; Diuresis; Glucosides; Kidney; Male; Myocardial Infarction; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Dysfunction, Left; Ventricular Function, Left | 2020 |
Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats.
Topics: Animals; Benzhydryl Compounds; Bisoprolol; Cardiovascular Agents; Chronic Disease; Disease Models, Animal; Exercise Tolerance; Fosinopril; Glucosides; Heart Failure; Male; Myocardial Infarction; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors; Spironolactone; Ventricular Dysfunction, Left; Ventricular Function, Left | 2020 |
Empagliflozin prevents doxorubicin-induced myocardial dysfunction.
Topics: Animals; Benzhydryl Compounds; Cardiomyopathies; Cardiotoxicity; Diastole; Disease Models, Animal; Doxorubicin; Extracellular Signal-Regulated MAP Kinases; Fibrosis; Glucosides; Male; Mice, Inbred C57BL; Myocytes, Cardiac; Sodium-Glucose Transporter 2 Inhibitors; Systole; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2020 |
Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury.
Topics: Animals; Apoptosis; Arrhythmias, Cardiac; Benzhydryl Compounds; Disease Models, Animal; Energy Metabolism; Glucosides; Male; Mitochondria, Heart; Mitochondrial Dynamics; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Dysfunction, Left; Ventricular Function, Left | 2020 |
Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Glucosides; GTP Cyclohydrolase; Male; Myocardial Infarction; Rats; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Dysfunction, Left; Ventricular Remodeling | 2020 |
Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure: A Multimodality Study.
Topics: Animals; Benzhydryl Compounds; Diastole; Fibrosis; Glucosides; Heart Failure; Heart Ventricles; Predictive Value of Tests; Stroke Volume; Swine; Ventricular Dysfunction, Left; Ventricular Function, Left | 2021 |
Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Female; Glucosides; Humans; Male; Middle Aged; Prospective Studies; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2021 |
Icarrin prevents cardiomyocyte apoptosis in spontaneously hypertensive rats by inhibiting endoplasmic reticulum stress pathways.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Flavonoids; Glucosides; Heart Ventricles; Hypertension; Myocytes, Cardiac; Protective Agents; Rats; Rats, Inbred SHR; Signal Transduction; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Remodeling | 2021 |
Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling.
Topics: Angiotensin II; Animals; Antifibrotic Agents; Benzhydryl Compounds; Cells, Cultured; Disease Models, Animal; Fibroblasts; Fibrosis; Glucosides; Hypertrophy, Left Ventricular; Male; Myocardium; Rats, Sprague-Dawley; Signal Transduction; Smad Proteins; Sodium-Glucose Transporter 2 Inhibitors; Transforming Growth Factor beta1; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2021 |
Impact of Dapagliflozin on the Left Ventricular Diastolic Function in Diabetic Patients with Heart Failure Complicating Cardiovascular Risk Factors.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diastole; Glucosides; Heart Disease Risk Factors; Heart Failure; Humans; Japan; Risk Factors; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2021 |
All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Case-Control Studies; Cause of Death; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Ischemic Attack, Transient; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Ischemia; Retrospective Studies; Stroke; Ventricular Dysfunction, Left | 2017 |
Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Calcium-Binding Proteins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucosides; Hypoglycemic Agents; Male; Mice; Models, Genetic; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Signal Transduction; Ventricular Dysfunction, Left | 2017 |
Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line : Editorial to: "Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes" by N. Hammoudi et al.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Models, Genetic; Ventricular Dysfunction, Left | 2017 |
Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury.
Topics: Animals; Benzhydryl Compounds; Cardiotonic Agents; Cytoprotection; Diet, High-Fat; Glucosides; Heart; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Rats; Rats, Wistar; Ventricular Dysfunction, Left; Ventricular Function, Left; Vildagliptin | 2018 |
Beneficial Effect of the SGLT2 Inhibitor Empagliflozin on Glucose Homeostasis and Cardiovascular Parameters in the Cohen Rosenthal Diabetic Hypertensive (CRDH) Rat.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Diabetes Mellitus; Disease Models, Animal; Glucosides; Homeostasis; Hypertension; Hypertrophy, Left Ventricular; Insulin Resistance; Kidney; Male; Pancreas; Proteinuria; Rats, Inbred SHR; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2018 |
Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction.
Topics: Animals; Benzhydryl Compounds; Carbonates; Disease Models, Animal; Glucosides; Hypertrophy, Left Ventricular; Male; Myocardial Infarction; Myocardium; Rats, Inbred F344; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2018 |
Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
Topics: Animals; Benzhydryl Compounds; Echocardiography; Energy Metabolism; Glucosides; Heart Failure; Myocardial Infarction; Rats; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2019 |
Diving into the unknown: sodium-glucose cotransporter-2 inhibitors in heart failure without diabetes.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Heart Failure; Myocardial Infarction; Rats; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Dysfunction, Left | 2019 |
The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cardiomyopathy, Hypertrophic; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Echocardiography; Fluorodeoxyglucose F18; Glucosides; GTP-Binding Protein gamma Subunits; Heart; Heterotrimeric GTP-Binding Proteins; Hyperglycemia; Hypoglycemic Agents; Lipodystrophy; Magnetic Resonance Imaging; Mice; Mice, Knockout; Myocardium; Pioglitazone; Positron-Emission Tomography; Radiopharmaceuticals; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Ventricular Dysfunction, Left; Ventricular Function | 2017 |
Paeoniflorin improves survival in LPS-challenged mice through the suppression of TNF-α and IL-1β release and augmentation of IL-10 production.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoates; Bridged-Ring Compounds; Cytokines; Echocardiography; Glucosides; Heart; Interleukin-10; Interleukin-1beta; Kidney; Kidney Function Tests; Lipopolysaccharides; Liver; Liver Function Tests; Lung; Male; Mice; Mice, Inbred BALB C; Monoterpenes; Myocardium; Pulmonary Edema; Survival Analysis; Tumor Necrosis Factor-alpha; Ventricular Dysfunction, Left | 2011 |